🇺🇸 D-Penicillamine in United States

146 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 146

Most-reported reactions

1. Joint Swelling — 20 reports (13.7%)
2. Drug Ineffective — 17 reports (11.64%)
3. Arthralgia — 16 reports (10.96%)
4. Red Blood Cell Sedimentation Rate Increased — 15 reports (10.27%)
5. Anaphylactic Reaction — 13 reports (8.9%)
6. Cardiovascular Disorder — 13 reports (8.9%)
7. Drug Hypersensitivity — 13 reports (8.9%)
8. Dystonia — 13 reports (8.9%)
9. Inflammation — 13 reports (8.9%)
10. Muscle Spasms — 13 reports (8.9%)

Source database →

Frequently asked questions

Is D-Penicillamine approved in United States?

D-Penicillamine does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for D-Penicillamine in United States?

Orphalan is the originator. The local marketing authorisation holder may differ — check the official source linked above.